Clin2
NCT06942104Possibly a fitRecruiting

New imaging agent for advanced solid tumors

Solid TumorSolid CarcinomaCastration-Resistant Prostate CarcinomaLocally Advanced Clear Cell Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaMetastatic Malignant Solid NeoplasmStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8

Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.

This trial tests a new imaging agent (18F-TRX) to see if it can better detect cancer spread in people with advanced solid tumors. It is designed for patients with specific cancers like high-grade brain tumors, advanced kidney cancer, or prostate cancer that has stopped responding to hormone therapy.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
56 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have a type of advanced cancer that has spread to other parts of the body (like brain tumors, kidney cancer, or prostate cancer that no longer responds to hormone therapy).
  • You are able to do most daily activities without help (fully active or limited to light work).
  • Your blood counts and organ function (liver, kidneys) are within certain safe levels.
  • You are not pregnant or breastfeeding.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07664397Not yet recruiting· Phase 1
Imaging study using a new tracer to find cancer

This trial tests a special imaging agent, [89Zr]DFO-YS5, to see if it can help detect and map certain cancers (including malignant peripheral nerve sheath tumors, bladder cancer, and other solid tumors) during PET scans. It may help doctors see cancerous lesions more clearly.

San Francisco, California
NCT06851663Recruiting· Phase 2/Phase 3
New PET scan for many solid tumors

This trial tests a new type of PET scan that uses a special antibody to find a marker called Trop2 on many common solid tumors. It may help doctors see tumors more clearly without needing a biopsy.

Shanghai
NCT07046702Recruiting
PET scan using a new tracer for solid tumors

This study tests whether a new imaging agent called 68Ga-MY6349 can help detect tumors during a PET/CT scan. If you are an adult with a solid tumor (newly diagnosed or already treated), you may be able to take part in this research to see if the new tracer works better than standard imaging.

Xiamen, Fujian
NCT06646952Recruiting
PET imaging of solid tumors with a CD147-targeting probe

This trial tests a special imaging agent (a nanobody probe) that targets a protein called CD147 on tumor cells. If you have a solid tumor like melanoma, liver, colorectal, pancreatic, breast, stomach, or lung cancer, the PET scan may help doctors see your cancer more clearly.

Beijing, Beijing Municipality
NCT06719856Recruiting
PET imaging study for multiple solid tumors

This trial uses a special PET scan to take pictures of certain solid tumors. The scan uses a new dye that may help doctors see the tumors more clearly. You may be eligible if you have one of the listed cancers and are between 18 and 75 years old with good daily function.

Beijing, Beijing Municipality
NCT07577206Recruiting· Early Phase 1
New PET Scan Tracer for Advanced Solid Cancers

This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.

Naples, Italia

Hear when a new Solid Tumor trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.